Evaxion Biotech A/S Receivables

Evaxion Biotech A/S (EVAX) currently reports a receivables of $1.9M as of June 2026. That compares with $860K in the prior-year period — up 115.0% year over year. Use the charts on this page to explore Evaxion Biotech A/S's receivables history and peer comparisons.

Evaxion Biotech A/S's receivables increased from $860K to $1.9M — a 115.0% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Evaxion Biotech A/S reported $1.9M in receivables as of June 2026. That compares with $860K in the prior-year period — up 115.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $1.9M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Evaxion Biotech A/S, and consider following EVAX for alerts when major investors trade the stock.

Evaxion Biotech A/S is classified in the Healthcare sector. On receivables, it currently shows $1.9M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing EVAX with unrelated industries.